ChromaDex Corporation (NAGE) - Forward Price-to-Revenue Multiple

Sales diversification across B2B and B2C segments ensures a stable cash flow from recurring contracts, and the GURU.Markets platform provides this chart of the company's projected P/S, where 4.60 represents the current metric. The monopoly position of Chromadex Corp (NAGE) in the cellular health niche is based on the ownership of fundamental patents and regulatory approvals.

The forward P/S ratio relates current market capitalization to projected annual revenue, determining the premium for expected business growth. By analyzing the forward P/S trajectory, an investor assesses the risk of asset overvaluation should expansion slow. High multiplier values are justified by the exclusive ownership of Niagen patents. This allows Chromadex Corp (NAGE) to maintain pricing power in the cellular rejuvenation sector, supporting high sales margins.